Cyclophosphamide inhibits the generation and function of CD8 + regulatory T cells

Ilaria Traverso, Daniela Fenoglio, Simone Negrini, Alessia Parodi, Florinda Battaglia, Francesca Kalli, Giuseppina Conteduca, Samuele Tardito, Paolo Traverso, Francesco Indiveri, Gilberto Filaci

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

CD8 + regulatory T cells (Treg) and CD4 +CD25 + Treg infiltrate human cancers, thus favoring tumor immune escape. Therefore, in the setting of antitumor therapeutic protocols, it is important to associate antitumor treatment with agents that are able to inhibit Treg function. Cyclophosphamide (CY) has been demonstrated to be effective in counteracting CD4 +CD25 + Treg activity. Hence, we tested its inhibitory efficacy on human CD8 + Treg. Because CY is a prodrug, 4-hydroperoxycyclophosphamide (4-HC), a derivative of CY that in aqueous solution is converted to 4-hydroxycyclophosphamide, an active metabolite of CY, was used. 4-HC significantly inhibited CD8 + Treg generation and function but only at the higher tested concentration (0.5 μg/mL), that is, in the therapeutic range of the drug. The lower 4-HC concentration tested (0.1 μg/mL) was almost ineffective. 4-HC inhibitory effects were related to apoptosis/necrosis induction. When CD8 +CD28 + non-Treg were analyzed for comparative purposes, significantly lower cytotoxic rates among these cells were observed than among CD8 + Treg, which were differentiated because they did not express the CD28 molecule. These data demonstrate that CD8 + Treg are inhibited through cytotoxic phenomena by CY, thus supporting the use of this drug at adequate concentrations and schedules of administration as a Treg inhibitor in combinatorial chemo- or immunotherapeutic anticancer protocols.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalHuman Immunology
Volume73
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

perfosfamide
Regulatory T-Lymphocytes
Cyclophosphamide
4-hydroxycyclophosphamide
Tumor Escape
Prodrugs
Pharmaceutical Preparations
Appointments and Schedules
Necrosis
Apoptosis
Therapeutics

Keywords

  • CD8
  • Cyclophosphamide
  • Treg Cancer Autoimmunity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Cyclophosphamide inhibits the generation and function of CD8 + regulatory T cells. / Traverso, Ilaria; Fenoglio, Daniela; Negrini, Simone; Parodi, Alessia; Battaglia, Florinda; Kalli, Francesca; Conteduca, Giuseppina; Tardito, Samuele; Traverso, Paolo; Indiveri, Francesco; Filaci, Gilberto.

In: Human Immunology, Vol. 73, No. 3, 03.2012, p. 207-213.

Research output: Contribution to journalArticle

Traverso, I, Fenoglio, D, Negrini, S, Parodi, A, Battaglia, F, Kalli, F, Conteduca, G, Tardito, S, Traverso, P, Indiveri, F & Filaci, G 2012, 'Cyclophosphamide inhibits the generation and function of CD8 + regulatory T cells', Human Immunology, vol. 73, no. 3, pp. 207-213. https://doi.org/10.1016/j.humimm.2011.12.020
Traverso, Ilaria ; Fenoglio, Daniela ; Negrini, Simone ; Parodi, Alessia ; Battaglia, Florinda ; Kalli, Francesca ; Conteduca, Giuseppina ; Tardito, Samuele ; Traverso, Paolo ; Indiveri, Francesco ; Filaci, Gilberto. / Cyclophosphamide inhibits the generation and function of CD8 + regulatory T cells. In: Human Immunology. 2012 ; Vol. 73, No. 3. pp. 207-213.
@article{8f2cef1a23d7463e90a013c1b9ec437f,
title = "Cyclophosphamide inhibits the generation and function of CD8 + regulatory T cells",
abstract = "CD8 + regulatory T cells (Treg) and CD4 +CD25 + Treg infiltrate human cancers, thus favoring tumor immune escape. Therefore, in the setting of antitumor therapeutic protocols, it is important to associate antitumor treatment with agents that are able to inhibit Treg function. Cyclophosphamide (CY) has been demonstrated to be effective in counteracting CD4 +CD25 + Treg activity. Hence, we tested its inhibitory efficacy on human CD8 + Treg. Because CY is a prodrug, 4-hydroperoxycyclophosphamide (4-HC), a derivative of CY that in aqueous solution is converted to 4-hydroxycyclophosphamide, an active metabolite of CY, was used. 4-HC significantly inhibited CD8 + Treg generation and function but only at the higher tested concentration (0.5 μg/mL), that is, in the therapeutic range of the drug. The lower 4-HC concentration tested (0.1 μg/mL) was almost ineffective. 4-HC inhibitory effects were related to apoptosis/necrosis induction. When CD8 +CD28 + non-Treg were analyzed for comparative purposes, significantly lower cytotoxic rates among these cells were observed than among CD8 + Treg, which were differentiated because they did not express the CD28 molecule. These data demonstrate that CD8 + Treg are inhibited through cytotoxic phenomena by CY, thus supporting the use of this drug at adequate concentrations and schedules of administration as a Treg inhibitor in combinatorial chemo- or immunotherapeutic anticancer protocols.",
keywords = "CD8, Cyclophosphamide, Treg Cancer Autoimmunity",
author = "Ilaria Traverso and Daniela Fenoglio and Simone Negrini and Alessia Parodi and Florinda Battaglia and Francesca Kalli and Giuseppina Conteduca and Samuele Tardito and Paolo Traverso and Francesco Indiveri and Gilberto Filaci",
year = "2012",
month = "3",
doi = "10.1016/j.humimm.2011.12.020",
language = "English",
volume = "73",
pages = "207--213",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Cyclophosphamide inhibits the generation and function of CD8 + regulatory T cells

AU - Traverso, Ilaria

AU - Fenoglio, Daniela

AU - Negrini, Simone

AU - Parodi, Alessia

AU - Battaglia, Florinda

AU - Kalli, Francesca

AU - Conteduca, Giuseppina

AU - Tardito, Samuele

AU - Traverso, Paolo

AU - Indiveri, Francesco

AU - Filaci, Gilberto

PY - 2012/3

Y1 - 2012/3

N2 - CD8 + regulatory T cells (Treg) and CD4 +CD25 + Treg infiltrate human cancers, thus favoring tumor immune escape. Therefore, in the setting of antitumor therapeutic protocols, it is important to associate antitumor treatment with agents that are able to inhibit Treg function. Cyclophosphamide (CY) has been demonstrated to be effective in counteracting CD4 +CD25 + Treg activity. Hence, we tested its inhibitory efficacy on human CD8 + Treg. Because CY is a prodrug, 4-hydroperoxycyclophosphamide (4-HC), a derivative of CY that in aqueous solution is converted to 4-hydroxycyclophosphamide, an active metabolite of CY, was used. 4-HC significantly inhibited CD8 + Treg generation and function but only at the higher tested concentration (0.5 μg/mL), that is, in the therapeutic range of the drug. The lower 4-HC concentration tested (0.1 μg/mL) was almost ineffective. 4-HC inhibitory effects were related to apoptosis/necrosis induction. When CD8 +CD28 + non-Treg were analyzed for comparative purposes, significantly lower cytotoxic rates among these cells were observed than among CD8 + Treg, which were differentiated because they did not express the CD28 molecule. These data demonstrate that CD8 + Treg are inhibited through cytotoxic phenomena by CY, thus supporting the use of this drug at adequate concentrations and schedules of administration as a Treg inhibitor in combinatorial chemo- or immunotherapeutic anticancer protocols.

AB - CD8 + regulatory T cells (Treg) and CD4 +CD25 + Treg infiltrate human cancers, thus favoring tumor immune escape. Therefore, in the setting of antitumor therapeutic protocols, it is important to associate antitumor treatment with agents that are able to inhibit Treg function. Cyclophosphamide (CY) has been demonstrated to be effective in counteracting CD4 +CD25 + Treg activity. Hence, we tested its inhibitory efficacy on human CD8 + Treg. Because CY is a prodrug, 4-hydroperoxycyclophosphamide (4-HC), a derivative of CY that in aqueous solution is converted to 4-hydroxycyclophosphamide, an active metabolite of CY, was used. 4-HC significantly inhibited CD8 + Treg generation and function but only at the higher tested concentration (0.5 μg/mL), that is, in the therapeutic range of the drug. The lower 4-HC concentration tested (0.1 μg/mL) was almost ineffective. 4-HC inhibitory effects were related to apoptosis/necrosis induction. When CD8 +CD28 + non-Treg were analyzed for comparative purposes, significantly lower cytotoxic rates among these cells were observed than among CD8 + Treg, which were differentiated because they did not express the CD28 molecule. These data demonstrate that CD8 + Treg are inhibited through cytotoxic phenomena by CY, thus supporting the use of this drug at adequate concentrations and schedules of administration as a Treg inhibitor in combinatorial chemo- or immunotherapeutic anticancer protocols.

KW - CD8

KW - Cyclophosphamide

KW - Treg Cancer Autoimmunity

UR - http://www.scopus.com/inward/record.url?scp=84857111372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857111372&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2011.12.020

DO - 10.1016/j.humimm.2011.12.020

M3 - Article

VL - 73

SP - 207

EP - 213

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 3

ER -